Table 3.
Reasons why physicians don’t follow or deviate from the guidelines
| Reasons | Geographical regions | Total n = 339a % (n) |
||||
|---|---|---|---|---|---|---|
| NA n = 236a % (n) |
LA n = 98a % (n) |
EU n = 167a % (n) |
AME n = 38a % (n) |
AP n = 104a % (n) |
||
| The guidelines do not undergo revision frequently enough | 4.2 (10) | 4.1 (4) | 3.0 (5) | 5.3 (2) | 6.7 (7) | 8.2 (28) |
| I rely more on my own clinical experience | 27.1 (64) | 10.2 (10) | 20.4 (34) | 34.2 (13) | 26.9 (28) | 43.9 (149) |
| I do not agree with the guidelines’ recommendations and/or conclusions | 7.2 (17) | 3.1 (3) | 4.2 (7) | 2.6 (1) | 3.8 (4) | 9.4 (32) |
| Some of the recommendations are unclear to me and require further details | 3.4 (8) | 1.0 (1) | 8.4 (14) | 2.6 (1) | 11.5 (12) | 10.6 (36) |
| Some of the guidelines’ recommendations cannot be implemented in my country of residence | 0.8 (2) | 14.3 (14) | 12.0 (20) | 26.3 (10) | 22.1 (23) | 20.3 (69) |
| I had a negative experience with following the guidelines in my clinical practice | 1.7 (4) | 0 (0) | 3.6 (6) | 2.6 (1) | 0 (0) | 3.2 (11) |
| Overly simplified approach to CSU management recommended by the guidelines that does not reflect the complexity of the disease | 22.9 (54) | 7.1 (7) | 15.6 (26) | 10.5 (4) | 9.6 (10) | 29.8 (101) |
| The discrepancy and/or disagreement between the guidelines | 3.0 (7) | 2.0 (2) | 1.8 (3) | 2.6 (1) | 0 (0) | 3.8 (13) |
AME Africa/Middle-East, AP Asia-Pacific, EU Europe, LA Latin America, NA North America. athe total number of respondents was 339. However, there was overlapping in the data analysis because respondents could choose more than one option